Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients : Insights from the MECKI score database
- S. Paolillo
- M. Mapelli
- A. Bonomi
- U. Corrã
- M. Piepoli
- F. Veglia
- E. Salvioni
- P. Gentile
- R. Lagioia
- M. Metra
- G. Limongelli
- G. Sinagra
- G. Cattadori
- A.B. Scardovi
- V. Carubelli
- D. Scrutino
- R. Badagliacca
- R. Raimondo
- M. Emdin
- D. Magrã
- M. Correale
- G. Parati
- S. Caravita
- E. Spadafora
- F. Re
- M. Cicoira
- M. Frigerio
- M. Bussotti
- C. Minã
- F. Oliva
- E. Battaia
- R. Belardinelli
- A. Mezzani
- L. Pastormerlo
- A. Di Lenarda
- C. Passino
- S. Sciomer
- A. Iorio
- E. Zambon
- M. Guazzi
- G. Pacileo
- R. Ricci
- M. Contini
- A. Apostolo
- P. Palermo
- F. Clemenza
- G. Marchese
- S. Binno
- C. Lombardi
- A. Passantino
- P. Perrone Filardi
- P. Agostoni
DOIAbstract
Aims: The use of \uce\ub2-blockers represents a milestone in the treatment of heart failure with reduced ejection fraction (HFrEF). Few studies have compared \uce\ub2-blockers in HFrEF, and there is little data on the effects of different doses. The present study aimed to investigate in a large database of HFrEF patients (MECKI score database) the association of \uce\ub2-blocker treatment with a composite outcome of cardiovascular death, urgent heart transplantation or left ventricular assist device implantation, addressing the role of \uce\ub2-selectivity and dosage regimens. Methods and results: In 5242 HFrEF patients, we investigated the role of: (i) \uce\ub2-blocker treatment vs. non-\uce\ub2-blocker treatment, (ii) \uce\ub21-/\uce\ub22...
Add to ORKG